CITIUS PHARMACEUTICALS INC (CTXR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.59-2.38%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CTXR
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 | Sep 2015 | Sep 2014 | Sep 2013 | Sep 2012 | Sep 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | — | — | — | — | 0.1 | 0.1 | 0.1 | 0.1 | — | — | — | — | — | 0.0 | 0.0 | 0.0 |
| Total Revenues | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.0 | 0.0 | 0.0 |
| Cost of Revenues | — | — | — | — | — | — | — | 0.1 | 0.1 | — | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| R&D Expenses | 5.9 | 9.2 | 11.9 | 14.8 | 17.7 | 12.2 | 8.8 | 8.6 | 6.6 | 2.9 | 2.9 | 1.8 | 0.5 | — | — | — |
| Other Operating Expenses, Total | — | — | — | — | 0.3 | 0.5 | — | — | — | — | — | — | — | — | — | — |
| Operating Income | (61.4) | (38.5) | (42.0) | (36.7) | (33.3) | (23.5) | (17.7) | (15.6) | (13.8) | (10.0) | (7.4) | (3.2) | (1.2) | (0.0) | (0.0) | (0.0) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | 0.3 | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.9 | 0.0 | 0.0 | 0.1 | — | 0.0 | — |
| Interest & Investment Income | 0.3 | 0.1 | 0.8 | 1.2 | 0.3 | 0.3 | 0.1 | 0.1 | 0.0 | 0.0 | — | — | — | — | — | — |
| Net Interest Expenses | — | — | — | — | — | (0.3) | (0.1) | (0.0) | 0.0 | 0.8 | — | — | — | — | — | — |
| Other Non-Operating Income / Expenses | 3.4 | (0.2) | 3.1 | 4.8 | 0.3 | 0.5 | 0.2 | 0.0 | 1.3 | (0.4) | (0.8) | 0.3 | (0.1) | — | — | (0.0) |
| EBT, Incl. Unusual Items | (58.0) | (38.7) | (38.8) | (32.0) | (33.1) | (23.1) | (17.5) | (15.6) | 12.5 | 10.4 | (8.3) | (2.9) | (1.3) | (0.0) | (0.0) | (0.0) |
| Income Tax Expense | 0.2 | 1.1 | 0.6 | 0.6 | 0.6 | 0.0 | 0.0 | — | — | — | — | — | — | 0.0 | 0.0 | 0.0 |
| Net Income | ||||||||||||||||
| Minority Interest | (11.9) | (2.3) | (0.3) | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Income | — | (39.7) | (39.4) | (32.5) | (33.6) | (23.1) | (17.5) | (15.6) | (12.5) | (10.4) | (8.3) | (2.9) | (1.3) | (0.0) | (0.0) | (0.0) |
| Per Share | ||||||||||||||||
| Basic EPS | — | (3.38) | (5.97) | (5.57) | (0.23) | (0.23) | — | — | — | — | — | — | — | 0.00 | 0.00 | — |
| Diluted EPS | — | (3.38) | (5.97) | (5.57) | (0.23) | (0.23) | — | — | — | — | — | — | — | 0.00 | 0.00 | — |
| Basic Weighted Avg Shares | 26.2 | 11.1 | 6.7 | 6.1 | 146.1 | 108.6 | — | — | — | — | — | — | — | 18.0 | 18.0 | — |
| Diluted Weighted Avg Shares | 26.2 | 11.1 | 6.7 | 6.1 | 146.1 | 108.6 | — | — | — | — | — | — | — | 18.0 | 18.0 | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | — | — | — | — | — | — | — | — | (10.0) | — | — | — | — | — | — |
| EBIT | (61.4) | (38.5) | (42.0) | (36.7) | (33.3) | (23.5) | (17.7) | (15.6) | (13.8) | (10.0) | (7.4) | (3.2) | (1.2) | (0.0) | (0.0) | (0.0) |
| Effective Tax Rate | -0.3% | — | — | -1.8% | -1.7% | -0.0% | -0.0% | — | — | — | — | — | — | 0.0% | 0.0% | 0.0% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.